Observational studyBMC gastroenterology2025
Insights into the treatment of infliximab and vedolizumab in positive PR3-ANCA patients with moderately to severely active ulcerative colitis: multicenter real-world evidence.
Qi Yu et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.